Systematic review with meta-analysis: rifaximin is effective and safe for the treatment of small intestine bacterial overgrowth

L Gatta, C Scarpignato, L Gatta, C Scarpignato

Abstract

Background: Small intestinal bacterial overgrowth (SIBO) is a heterogeneous syndrome, characterised by an increased number and/or abnormal type of bacteria in the small bowel. Over the past decades, rifaximin has gained popularity for this indication despite its use is not evidence based.

Aim: To perform a systematic review and meta-analysis to summarise evidence about the efficacy and safety of rifaximin to eradicate SIBO in adult patients.

Methods: MEDLINE, EMBASE, CCRCT, Scopus and Web of Science were searched from inception to March 16, 2015 for RCTs and observational studies. Furthermore, abstract books of major European, American and Asian gastroenterological meetings were also examined.

Results: Thirty-two studies involving 1331 patients were included. The overall eradication rate according to intention-to-treat analysis was 70.8% (95% CI: 61.4-78.2; I2 = 89.4%) and to per protocol analysis 72.9% (95% CI: 65.5-79.8; I2 = 87.5%). Meta-regression identified three covariates (drug dose, study design and co-therapy) independently associated with an increased eradication rate. The overall rate of adverse events was 4.6% (95% CI: 2.3-7.5; I2 = 63.6%). In the subset of studies (n= 10) allowing the analysis, improvement or resolution of symptoms in patients with eradicated SIBO was found to be 67.7% (95% CI: 44.7-86.9; I2 = 91.3%).

Conclusions: Rifaximin treatment seems to be effective and safe for the treatment of SIBO. However, the quality of the available studies is generally poor. Well-designed RCTs are needed to substantiate these findings and to establish the optimal regimen.

© 2017 The Authors. Alimentary Pharmacology and Therapeutics Published by John Wiley & Sons Ltd.

Figures

Figure 1
Figure 1
PRISMA flow diagram of the systematic review.
Figure 2
Figure 2
Forest plot of SIBO eradication rate according to ITT analysis.
Figure 3
Figure 3
Meta‐regression plot: logit of eradication rate vs. daily dose of rifaximin (adjusted for all the other covariates evaluated).
Figure 4
Figure 4
Forest plot of SIBO eradication rate in IBS patients according to ITT analysis.
Figure 5
Figure 5
Forest plot of adverse events in patients taking rifaximin alone.

References

    1. Scarpignato C, Gatta L. Commentary: towards an effective and safe treatment of small intestine bacterial overgrowth. Aliment Pharmacol Ther 2013; 38: 1409–10.
    1. Quigley EM. Small intestinal bacterial overgrowth: what it is and what it is not. Curr Opin Gastroenterol 2014; 30: 141–6.
    1. Quigley EM, Abu‐Shanab A. Small intestinal bacterial overgrowth. Infect Dis Clin North Am 2010; 24: 943–59.
    1. Khoshini R, Dai SC, Lezcano S, Pimentel M. A systematic review of diagnostic tests for small intestinal bacterial overgrowth. Dig Dis Sci 2008; 53: 1443–54.
    1. Rana SV, Sharma S, Kaur J, Sinha SK, Singh K. Comparison of lactulose and glucose breath test for diagnosis of small intestinal bacterial overgrowth in patients with irritable bowel syndrome. Digestion 2012; 85: 243–7.
    1. Abu‐Shanab A, Quigley EMM. Diagnosis of small intestinal bacterial overgrowth: the challenges persist!. Expert Rev Gastroenterol Hepatol 2009; 3: 77–87.
    1. Corazza GR, Di Stefano M, Scarpignato C. Treatment of functional bowel disorders: is there room for antibiotics? Digestion 2006; 73(Suppl. 1): 38–46.
    1. Sullivan A, Edlund C, Nord CE. Effect of antimicrobial agents on the ecological balance of human microflora. Lancet Infect Dis 2001; 1: 101–14.
    1. Marchi E, Montecchi L, Venturini AP, Mascellani G, Brufani M, Cellai L. 4‐Deoxypyrido[1',2':1,2]imidazo[5,4‐c]rifamycin SV derivatives. A new series of semisynthetic rifamycins with high antibacterial activity and low gastroenteric absorption. J Med Chem 1985; 28: 960–3.
    1. Scarpignato C, Pelosini I. Rifaximin, a poorly absorbed antibiotic: pharmacology and clinical potential. Chemotherapy 2005; 51(Suppl. 1): 36–66.
    1. Calanni F, Renzulli C, Barbanti M, Viscomi GC. Rifaximin: beyond the traditional antibiotic activity. J Antibiot 2014; 67: 667–70.
    1. Jiang ZD, Dupont HL. Rifaximin: in vitro and in vivo antibacterial activity‐a review. Chemotherapy 2005; 51(Suppl. 1): 67–72.
    1. Adachi JA, Dupont HL. Rifaximin: a novel nonabsorbed rifamycin for gastrointestinal disorders. Clin Infect Dis 2006; 42: 541–7.
    1. DuPont HL, Ericsson CD. Prevention and treatment of traveler's diarrhea. N Engl J Med 1993; 328: 1821–7.
    1. Liberati A, Altman DG, Tetzlaff J, et al The PRISMA statement for reporting systematic reviews and meta‐analyses of studies that evaluate health care interventions: explanation and elaboration. Ann Intern Med 2009; 151: W65–94.
    1. Stroup DF, Berlin JA, Morton SC, et al Meta‐analysis of observational studies in epidemiology: a proposal for reporting. Meta‐analysis Of Observational Studies in Epidemiology (MOOSE) group. JAMA 2000; 283: 2008–12.
    1. Dekkers OM, Egger M, Altman DG, Vandenbroucke JP. Distinguishing case series from cohort studies. Ann Intern Med 2012; 156: 37–40.
    1. Hoffman JT, Altman DG, Sterne JAC. Assessing risk of bias in included studies In: Higgins JPT, Green S, eds. Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (Updated March 2011): The Cochrane Collaboration, 2011. Available at: (accessed 10 December 2016)
    1. Wells GA, Shea B, O'Connell D, et al The Newcastle‐Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta‐analyses. Available at: clinical_epidemiology/oxford.htm (accessed May 2015).
    1. Guo B, Moga C, Harstall C, Schopflocher D. A principal component analysis is conducted for a case series quality appraisal checklist. J Clin Epidemiol 2016; 69: 199–207. e2.
    1. DerSimonian R. Meta‐analysis in the design and monitoring of clinical trials. Stat Med 1996; 15: 1237–48.
    1. Borenstein M. Introduction to Meta‐Analysis. Chichester, UK: John Wiley & Sons, 2009.
    1. Sedgwick P. What is per protocol analysis? BMJ 2013; 346: f3748–f48.
    1. Schünemann J, Oxman AD, Vist GE, et al Interpreting results and drawing conclusions In: Higgins JPT, Green S, eds. Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (Updated March 2011): The Cochrane Collaboration. Available at: (accessed 10 December 2016).
    1. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta‐analyses. BMJ 2003; 327: 557–60.
    1. Harbord RM, Higgins JP. Meta‐regression in Stata. Stata J 2008; 8: 493–519.
    1. Kleinbaum DG, Klein M, Pryor ER. Logistic Regression: A Self‐Learning Text. 3rd ed New York: Springer, 2010.
    1. Egger M, Davey SG, Schneider M, Minder C. Bias in meta‐analysis detected by a simple, graphical test. BMJ 1997; 315: 629–34.
    1. Corazza GR, Ventrucci M, Strocchi A, et al Treatment of small intestine bacterial overgrowth with rifaximin, a non‐absorbable rifamycin. J Int Med Res 1988; 16: 312–6.
    1. Biancone L, Vernia P, Agostini D, Ferrieri A, Pallone F. Effect of rifaximin on intestinal bacterial overgrowth in Crohn's disease as assessed by the H2‐Glucose Breath Test. Curr Med Res Opin 2000; 16: 14–20.
    1. Di Stefano M, Malservisi S, Veneto G, Ferrieri A, Corazza GR. Rifaximin versus chlortetracycline in the short‐term treatment of small intestinal bacterial overgrowth. Aliment Pharmacol Ther 2000; 14: 551–6.
    1. Cuoco L, Montalto M, Jorizzo RA, et al Eradication of small intestinal bacterial overgrowth and oro‐cecal transit in diabetics. Hepatogastroenterology 2002; 49: 1582–6.
    1. Tursi A, Brandimarte G, Giorgetti G. High prevalence of small intestinal bacterial overgrowth in celiac patients with persistence of gastrointestinal symptoms after gluten withdrawal. Am J Gastroenterol 2003; 98: 839–43.
    1. Lauritano EC, Gabrielli M, Lupascu A, et al Rifaximin dose‐finding study for the treatment of small intestinal bacterial overgrowth. Aliment Pharmacol Ther 2005; 22: 31–5.
    1. Tursi A, Brandimarte G, Giorgetti GM, Elisei W. Assessment of small intestinal bacterial overgrowth in uncomplicated acute diverticulitis of the colon. World J Gastroenterol 2005; 11: 2773–6.
    1. Cazzato A, Scarpellini E, Gabrielli M, et al Small intestinal bacterial overgrowth (SIBO) in patients with non‐erosive reflux esophagitis (NERD). Gastroenterology 2006; 130(Suppl. 2): W1083.
    1. Cuoco L, Salvagnini M. Small intestine bacterial overgrowth in irritable bowel syndrome: a retrospective study with rifaximin. Minerva Gastroenterol Dietol 2006; 52: 89–95.
    1. D'Inca R, Pomerri F, Vettorato MG, et al Interaction between rifaximin and dietary fibre in patients with diverticular disease. Aliment Pharmacol Ther 2007; 25: 771–9.
    1. Esposito I, de Leone A, Di Gregorio G, et al Breath test for differential diagnosis between small intestinal bacterial overgrowth and irritable bowel disease: an observation on non‐absorbable antibiotics. World J Gastroenterol 2007; 13: 6016–21.
    1. Lauritano EC, Bilotta AL, Gabrielli M, et al Association between hypothyroidism and small intestinal bacterial overgrowth. J Clin Endocrinol Metab 2007; 92: 4180–4.
    1. Majewski M, McCallum RW. Results of small intestinal bacterial overgrowth testing in irritable bowel syndrome patients: clinical profiles and effects of antibiotic trial. Adv Med Sci 2007; 52: 139–42.
    1. Majewski M, Reddymasu SC, Sostarich S, Foran P, McCallum RW. Efficacy of rifaximin, a nonabsorbed oral antibiotic, in the treatment of small intestinal bacterial overgrowth. Am J Med Sci 2007; 333: 266–70.
    1. Resmini E, Parodi A, Savarino V, et al Evidence of prolonged orocecal transit time and small intestinal bacterial overgrowth in acromegalic patients. J Clin Endocrinol Metab 2007; 92: 2119–24.
    1. Scarpellini E, Gabrielli M, Lauritano CE, et al High dosage rifaximin for the treatment of small intestinal bacterial overgrowth. Aliment Pharmacol Ther 2007; 25: 781–6.
    1. Yang J, Lee HR, Low K, Chatterjee S, Pimentel M. Rifaximin versus other antibiotics in the primary treatment and retreatment of bacterial overgrowth in IBS. Dig Dis Sci 2008; 53: 169–74.
    1. Parodi A, Sessarego M, Greco A, et al Small intestinal bacterial overgrowth in patients suffering from scleroderma: clinical effectiveness of its eradication. Am J Gastroenterol 2008; 103: 1257–62.
    1. Parodi A, Paolino S, Greco A, et al Small intestinal bacterial overgrowth in rosacea: clinical effectiveness of its eradication. Clin Gastroenterol Hepatol 2008; 6: 759–64.
    1. Lauritano EC, Gabrielli M, Scarpellini E, et al Antibiotic therapy in small intestinal bacterial overgrowth: rifaximin versus metronidazole. Eur Rev Med Pharmacol Sci 2009; 13: 111–6.
    1. Parodi A, Dulbecco P, Savarino E, et al Positive glucose breath testing is more prevalent in patients with IBS‐like symptoms compared with controls of similar age and gender distribution. J Clin Gastroenterol 2009; 43: 962–6.
    1. Peralta S, Cottone C, Doveri T, Almasio PL, Craxi A. Small intestine bacterial overgrowth and irritable bowel syndrome‐related symptoms: experience with Rifaximin. World J Gastroenterol 2009; 15: 2628–31.
    1. Furnari M, Parodi A, Gemignani L, et al Clinical trial: the combination of rifaximin with partially hydrolysed guar gum is more effective than rifaximin alone in eradicating small intestinal bacterial overgrowth. Aliment Pharmacol Ther 2010; 32: 1000–6.
    1. Lauritano EC, Valenza V, Sparano L, et al Small intestinal bacterial overgrowth and intestinal permeability. Scand J Gastroenterol 2010; 45: 1131–2.
    1. Lombardo L, Foti M, Ruggia O, Chiecchio A. Increased incidence of small intestinal bacterial overgrowth during proton pump inhibitor therapy. Clin Gastroenterol Hepatol 2010; 8: 504–8.
    1. Cerda E, Minero Alfano JJ, Gerrera Gonzalez J, et al Effect of rifaximin in small intestine bacterial overgrowth in patients with irritable bowel syndrome. Gut 2012; 61: A422.
    1. Meyrat P, Safroneeva E, Schoepfer AM. Rifaximin treatment for the irritable bowel syndrome with a positive lactulose hydrogen breath test improves symptoms for at least 3 months. Aliment Pharmacol Ther 2012; 36: 1084–93.
    1. Fasano A, Bove F, Gabrielli M, et al The role of small intestinal bacterial overgrowth in Parkinson's disease. Mov Disord 2013; 28: 1241–9.
    1. Boltin D, Perets TT, Shporn E, et al Rifaximin for small intestinal bacterial overgrowth in patients without irritable bowel syndrome. Ann Clin Microbiol Antimicrob 2014; 13: 49.
    1. Chedid V, Dhalla S, Clarke JO, et al Herbal therapy is equivalent to rifaximin for the treatment of small intestinal bacterial overgrowth. Glob Adv Health Med 2014; 3: 16–24.
    1. Moraru IG, Moraru AG, Andrei M, et al Small intestinal bacterial overgrowth is associated to symptoms in irritable bowel syndrome. Evidence from a multicentre study in Romania. Rom J Intern Med 2014; 52: 143–50.
    1. Gravina A, Federico A, Ruocco E, et al Helicobacter pylori infection but not small intestinal bacterial overgrowth may play a pathogenic role in rosacea. UEG J 2015; 3: 17–24.
    1. Bohm M, Siwiec RM, Wo JM. Diagnosis and management of small intestinal bacterial overgrowth. Nutr Clin Pract 2013; 28: 289–99.
    1. Baker DE. Rifaximin: a nonabsorbed oral antibiotic. Rev Gastroenterol Disord 2005; 5: 19–30.
    1. Maccaferri S, Vitali B, Klinder A, et al Rifaximin modulates the colonic microbiota of patients with Crohn's disease: an in vitro approach using a continuous culture colonic model system. J Antimicrob Chemother 2010; 65: 2556–65.
    1. Ponziani FR, Scaldaferri F, Petito V, et al Rifaximin treatment increases lactobacillus abundance in patients with different gastrointestinal and liver diseases. UEG Journal 2015; 3(5S): A138.
    1. Pocock SJ. Clinical Trials: A Practical Approach. Chichester, West Sussex; New York: Wiley, 1983.
    1. Concato J, Shah N, Horwitz RI. Randomized, controlled trials, observational studies, and the hierarchy of research designs. N Engl J Med 2000; 342: 1887–92.
    1. Benson K, Hartz AJ. A comparison of observational studies and randomized, controlled trials. N Engl J Med 2000; 342: 1878–86.
    1. Ioannidis JP, Haidich AB, Pappa M, et al Comparison of evidence of treatment effects in randomized and nonrandomized studies. JAMA 2001; 286: 821–30.
    1. Andrews CN, Griffiths TA, Kaufman J, Vergnolle N, Surette MG, Rioux KP. Mesalazine (5‐aminosalicylic acid) alters faecal bacterial profiles, but not mucosal proteolytic activity in diarrhoea‐predominant irritable bowel syndrome. Aliment Pharmacol Ther 2011; 34: 374–83.
    1. Kaufman J, Griffiths TA, Surette MG, Ness S, Rioux KP. Effects of mesalamine (5‐aminosalicylic acid) on bacterial gene expression. Inflamm Bowel Dis 2009; 15: 985–96.
    1. Xue L, Huang Z, Zhou X, Chen W. The possible effects of mesalazine on the intestinal microbiota. Aliment Pharmacol Ther 2012; 36: 813–4.
    1. Marchesi JR, Adams DH, Fava F, et al The gut microbiota and host health: a new clinical frontier. Gut 2016; 65: 330–9.
    1. Angelakis E, Merhej V, Raoult D. Related actions of probiotics and antibiotics on gut microbiota and weight modification. Lancet Infect Dis 2013; 13: 889–99.
    1. Hamaker BR, Tuncil YE. A perspective on the complexity of dietary fiber structures and their potential effect on the gut microbiota. J Mol Biol 2014; 426: 3838–50.
    1. Wallace TC, Guarner F, Madsen K, et al Human gut microbiota and its relationship to health and disease. Nutr Rev 2011; 69: 392–403.
    1. Ghoshal UC, Srivastava D, Ghoshal U, Misra A. Breath tests in the diagnosis of small intestinal bacterial overgrowth in patients with irritable bowel syndrome in comparison with quantitative upper gut aspirate culture. Eur J Gastroenterol Hepatol 2014; 26: 753–60.
    1. Kasir R, Zakko S, Zakko P, et al Predicting a response to antibiotics in patients with the irritable bowel syndrome. Dig Dis Sci 2016; 61: 846–51.
    1. Gupta A, Chey WD. Breath testing for small intestinal bacterial overgrowth: a means to enrich rifaximin responders in IBS patients? Am J Gastroenterol 2016; 111: 305–6.
    1. Pimentel M, Lembo A, Chey WD, et al Rifaximin therapy for patients with irritable bowel syndrome without constipation. N Engl J Med 2011; 364: 22–32.
    1. Saad RJ, Chey WD. Breath testing for small intestinal bacterial overgrowth: maximizing test accuracy. Clin Gastroenterol Hepatol 2013; 12: 1964–72.
    1. Shah SC, Day LW, Somsouk M, Sewell JL. Meta‐analysis: antibiotic therapy for small intestinal bacterial overgrowth. Aliment Pharmacol Ther 2013; 38: 925–34.
    1. Collins BS, Lin HC. Double‐blind, placebo‐controlled antibiotic treatment study of small intestinal bacterial overgrowth in children with chronic abdominal pain. J Pediatr Gastroenterol Nutr 2011; 52: 382–6.
    1. Chang MS, Minaya MT, Cheng J, Connor BA, Lewis SK, Green PH. Double‐blind randomized controlled trial of rifaximin for persistent symptoms in patients with celiac disease. Dig Dis Sci 2011; 56: 2939–46.
    1. Ioannidis JP, Lau J. Completeness of safety reporting in randomized trials: an evaluation of 7 medical areas. JAMA 2001; 285: 437–43.
    1. Ioannidis JP, Evans SJ, Gotzsche PC, et al Better reporting of harms in randomized trials: an extension of the CONSORT statement. Ann Intern Med 2004; 141: 781–8.
    1. Golder S, Loke YK, Bland M. Meta‐analyses of adverse effects data derived from randomised controlled trials as compared to observational studies: methodological overview. PLoS Med 2011; 8: e1001026.
    1. Baker WL, White CM, Cappelleri JC, et al Understanding heterogeneity in meta‐analysis: the role of meta‐regression. Int J Clin Pract 2009; 63: 1426–34.
    1. Yusuf S, Wittes J, Probstfield J, Tyroler HA. Analysis and interpretation of treatment effects in subgroups of patients in randomized clinical trials. JAMA 1991; 266: 93–8.
    1. Di Stefano M, Miceli E, Missanelli A, Mazzocchi S, Corazza GR. Absorbable vs. non‐absorbable antibiotics in the treatment of small intestine bacterial overgrowth in patients with blind‐loop syndrome. Aliment Pharmacol Ther 2005; 21: 985–92.
    1. Juni P, Altman DG, Egger M. Systematic reviews in health care: assessing the quality of controlled clinical trials. BMJ 2001; 323: 42–6.
    1. Reeves BC, Deeks JJ, Higgins JP, Welles GA. Including non‐randomized studies In: Higgins JPT, Green S, eds. Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (Updated March 2011): The Cochrane Collaboration. Available at: (accessed 10 December 2016).
    1. Dalziel K, Round A, Stein K, Garside R, Castelnuovo E, Payne L. Do the findings of case series studies vary significantly according to methodological characteristics? Health Technol Assess 2005; 9: iii–iv, 1–146.
    1. Stein K, Dalziel K, Garside R, Castelnuovo E, Round A. Association between methodological characteristics and outcome in health technology assessments which included case series. Int J Technol Assess Health Care 2005; 21: 277–87.
    1. Sterne JA, Sutton AJ, Ioannidis JP, et al Recommendations for examining and interpreting funnel plot asymmetry in meta‐analyses of randomised controlled trials. BMJ 2011; 343: d4002.
    1. Guyatt GH, Oxman AD, Vist GE, et al GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ 2008; 336: 924–6.

Source: PubMed

Sponzoři a spolupracovníci

Zdravotní podmínky

Drogové intervence

3
Předplatit